Sickle Cell Disease Pathophysiology and Related Molecular and Biophysical Biomarkers
Overview
Affiliations
One of the challenges in sickle cell disease is its clinical variability. Our ability to identify the complications that a patient is at risk for is limited by a lack of validated diagnostic and prognostic biomarkers. Clinical care is limited by a lack of diagnostics to capture the biological variability needed to precisely direct patient care. Many biomarkers have been proposed, but few validated. We must make a concerted effort as a field to rigorously test proposed biomarkers to improve outcomes for our patients.
Quang T, Mostashari G, Berning E, Gopalan B, Lizarralde-Iragorri M, Lovins D Biomed Opt Express. 2024; 15(8):4829-4841.
PMID: 39346999 PMC: 11427197. DOI: 10.1364/BOE.527770.
Multidisciplinary approaches to study anaemia with special mention on aplastic anaemia (Review).
Sankar D, Oviya I Int J Mol Med. 2024; 54(5).
PMID: 39219286 PMC: 11410310. DOI: 10.3892/ijmm.2024.5419.
Kaminski T, Sivanantham A, Mozhenkova A, Smith A, Ungalara R, Dubey R Am J Physiol Cell Physiol. 2024; 327(2):C423-C437.
PMID: 38682236 PMC: 11427010. DOI: 10.1152/ajpcell.00386.2023.
Lactate dehydrogenase and hemolysis index to predict vaso-occlusive crisis in sickle cell disease.
Feugray G, Dumesnil C, Grall M, Benhamou Y, Girot H, Fettig J Sci Rep. 2023; 13(1):21198.
PMID: 38040880 PMC: 10692321. DOI: 10.1038/s41598-023-48324-w.